drugset / Trial / NCT00553618
Adjuvant, Combined Interleukin 2 (Proleukin) and DTIC (Dacarbazine) in High-risk Melanoma Patients
Phase 2
Active not recruiting
160 enrolled
University of Louisville
James Graham Brown Cancer Center · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to see if the combination of the two cancer drugs, Dacarbazine (DTIC) and a low-dose of Proleukin (IL2), would provide a less toxic and more effective treatment for melanoma than currently available treatments for people with high-risk melanoma. Dacarbazine (DTIC) and Proleukin (IL2) are both FDA-approved drugs for the treatment of melanoma.
Timeline
- Start
- 2007-08
- Primary completion
- 2025-08
- Completion
- 2026-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dacarbazine | Small molecule | 750 mg | Intravenous |
| Subject | aldesleukin | Protein / enzyme biologic | 1.2e+07 iu | Subcutaneous |